These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25937185)

  • 1. Follistatin-like 3 is a mediator of exercise-driven bone formation and strengthening.
    Nam J; Perera P; Gordon R; Jeong YH; Blazek AD; Kim DG; Tee BC; Sun Z; Eubank TD; Zhao Y; Lablebecioglu B; Liu S; Litsky A; Weisleder NL; Lee BS; Butterfield T; Schneyer AL; Agarwal S
    Bone; 2015 Sep; 78():62-70. PubMed ID: 25937185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice.
    Xia Y; Sidis Y; Schneyer A
    Mol Endocrinol; 2004 Apr; 18(4):979-94. PubMed ID: 14739256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis.
    Brown ML; Bonomi L; Ungerleider N; Zina J; Kimura F; Mukherjee A; Sidis Y; Schneyer A
    Obesity (Silver Spring); 2011 Oct; 19(10):1940-9. PubMed ID: 21546932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Protein Kinase A in Mature Osteoblasts Promotes a Major Bone Anabolic Response.
    Tascau L; Gardner T; Anan H; Yongpravat C; Cardozo CP; Bauman WA; Lee FY; Oh DS; Tawfeek HA
    Endocrinology; 2016 Jan; 157(1):112-26. PubMed ID: 26488807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential actions of follistatin and follistatin-like 3.
    Schneyer A; Sidis Y; Xia Y; Saito S; del Re E; Lin HY; Keutmann H
    Mol Cell Endocrinol; 2004 Oct; 225(1-2):25-8. PubMed ID: 15451564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E11/gp38 selective expression in osteocytes: regulation by mechanical strain and role in dendrite elongation.
    Zhang K; Barragan-Adjemian C; Ye L; Kotha S; Dallas M; Lu Y; Zhao S; Harris M; Harris SE; Feng JQ; Bonewald LF
    Mol Cell Biol; 2006 Jun; 26(12):4539-52. PubMed ID: 16738320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
    Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
    Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
    Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
    Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
    Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
    FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.
    Mukherjee A; Sidis Y; Mahan A; Raher MJ; Xia Y; Rosen ED; Bloch KD; Thomas MK; Schneyer AL
    Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1348-53. PubMed ID: 17229845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of an osteocyte-like cell line, MLO-Y4.
    Kato Y; Windle JJ; Koop BA; Mundy GR; Bonewald LF
    J Bone Miner Res; 1997 Dec; 12(12):2014-23. PubMed ID: 9421234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FSTL3 is increased in renal dysfunction.
    Kralisch S; Hoffmann A; Klöting N; Bachmann A; Kratzsch J; Stolzenburg JU; Dietel A; Beige J; Anders M; Bast I; Blüher M; Zhang MZ; Harris RC; Stumvoll M; Fasshauer M; Ebert T
    Nephrol Dial Transplant; 2017 Oct; 32(10):1637-1644. PubMed ID: 28339962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiology of Activins/Follistatins: Associations With Metabolic and Anthropometric Variables and Response to Exercise.
    Perakakis N; Mougios V; Fatouros I; Siopi A; Draganidis D; Peradze N; Ghaly W; Mantzoros CS
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3890-3899. PubMed ID: 30085147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor β (TGFβ) signaling is essential for testicular aging and regulating testis size.
    Oldknow KJ; Seebacher J; Goswami T; Villen J; Pitsillides AA; O'Shaughnessy PJ; Gygi SP; Schneyer AL; Mukherjee A
    Endocrinology; 2013 Mar; 154(3):1310-20. PubMed ID: 23407452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis.
    Borton AJ; Frederick JP; Datto MB; Wang XF; Weinstein RS
    J Bone Miner Res; 2001 Oct; 16(10):1754-64. PubMed ID: 11585338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follistatin-like 1 as a Novel Adipomyokine Related to Insulin Resistance and Physical Activity.
    Xu X; Zhang T; Mokou M; Li L; Li P; Song J; Liu H; Zhu Z; Liu D; Yang M; Yang G
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32894773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsia.
    Guo J; Tian T; Lu D; Xia G; Wang H; Dong M
    J Obstet Gynaecol Res; 2012 Jul; 38(7):988-96. PubMed ID: 22568578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species.
    Zhou H; Newnum AB; Martin JR; Li P; Nelson MT; Moh A; Fu XY; Yokota H; Li J
    Bone; 2011 Sep; 49(3):404-11. PubMed ID: 21555004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased maternal and placental concentrations of follistatin-like 3 in gestational diabetes.
    Hu D; Tian T; Guo J; Wang H; Chen D; Dong M
    Clin Chim Acta; 2012 Mar; 413(5-6):533-6. PubMed ID: 22122995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen.
    Zaman G; Jessop HL; Muzylak M; De Souza RL; Pitsillides AA; Price JS; Lanyon LL
    J Bone Miner Res; 2006 Aug; 21(8):1297-306. PubMed ID: 16869728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.